Breast adenocarcinoma cell adhesion to the vascular subendothelium in whole blood and under flow conditions: effects of alphavbeta3 and alphaIIbbeta3 antagonists.
Tumour cell adhesion to vascular extracellular matrix (ECM), an important step of metastatic progression, is promoted by platelets. The aim of our study was to investigate, in whole blood under venous and arterial shear conditions, the respective role of tumour cell alphavbeta3 and platelet alphaIIbbeta3 integrins in MDA-MB-231 breast adenocarcinoma cell adhesion to human umbilical vein endothelial cell ECM. For that purpose, blood containing MDA-MB-231 cells was incubated with non-peptide antagonists specific for platelet alphaIIbbeta3 (lamifiban) or tumour cell alphavbeta3 (SB-273005). At 300 s(-1), each antagonist used alone did not modify tumour cell adhesion, whereas, at 1500 s(-1), tumour cell adhesion was decreased by 25% in presence of lamifiban indicating a role of platelet alphaIIbbeta3 at higher shear rate. However, a combination of SB-273005 and lamifiban, or c7E3 Fab (a potent inhibitor of both alphaIIbbeta3 and alphavbeta3) inhibited tumour cell adhesion by 40-45%, at either shear rate applied, indicating a cooperation between these two integrins in MDA-MB-231 cell adhesion to ECM, as well as the participation of other adhesive receptors on tumour cells and/or platelets. Thus, efficient anti-metastatic therapy should target multiple receptors on tumour cells and platelets.
Gomes
Noëlia
N
INSERM, U 553 Hémostase, Endothélium et Angiogénèse, IFR 105, Institut d'Hématologie, Université Paris VII Denis Diderot, Hôpital Saint-Louis 1, Paris, France.
Vassy
Jany
J
Lebos
Claude
C
Arbeille
Brigitte
B
Legrand
Chantal
C
Fauvel-Lafeve
Françoise
F
D000077284:Abciximab; D000085:Acetates / Q000494:pharmacology; D000230:Adenocarcinoma / Q000378:metabolism* / Q000473:pathology; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001792:Blood Platelets / Q000378:metabolism; D001808:Blood Vessels; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology; D002448:Cell Adhesion; D004730:Endothelium, Vascular / Q000378:metabolism* / Q000473:pathology; D005109:Extracellular Matrix / Q000378:metabolism; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000494:pharmacology; D039302:Integrin alphaVbeta3 / Q000037:antagonists & inhibitors*; D010973:Platelet Adhesiveness; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011725:Pyridines / Q000494:pharmacology; D019030:Receptors, Vitronectin / Q000037:antagonists & inhibitors; D012039:Regional Blood Flow; D014407:Tumor Cells, Cultured; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000494:pharmacology
D000085:Acetates; D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D039302:Integrin alphaVbeta3; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011725:Pyridines; D019030:Receptors, Vitronectin; C420822:SB 273005; D014443:Tyrosine; C084062:lamifiban; D000077284:Abciximab